Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK0653A
MK0653A, ezetimibe simvastatin · 8 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| MK0653A, ezetimibe (+) simvastatin | DRUG | - |
| Duration of Treatment: 4 wk placebo run in then 6 wk active | DRUG | - |
| Comparator: atorvastatin | DRUG | - |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks | DRUG | - |
| Comparator: atorvastatin / Duration of Treatment: 6 Weeks | DRUG | - |
| MK0653A (ezetimibe [+] simvastatin) | DRUG | - |
| Comparator: fluvastatin | DRUG | - |
| Comparator: lovastatin | DRUG | - |
| Comparator: pravastatin | DRUG | - |
| Comparator: rosuvastatin | DRUG | - |
| Comparator: simvastatin | DRUG | - |
| MK0653A , ezetimibe (+) simvastatin | DRUG | - |
| Duration of Treatment: 6 weeks | DRUG | - |
| MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks | DRUG | - |
| Comparators: simvastatin and ezetimibe | DRUG | - |
Inclusion Criteria: * Men and women aged 18 to 79 years who have a confirmed diagnosis of type 2 diabetes mellitus with elevated cholesterol levels may be eligible to participate in a study to assess the efficacy and safety of the two marketed drugs. Exclusion Criteria: * Type 1 Diabetes Mellitus...
Top 13 of 17 competitors
MK0653A is a combination of ezetimibe and simvastatin studied for hypercholesterolemia and type 2 diabetes mellitus. It is a small molecule therapy developed by Organon & Co. (OGN) and has been investigated in Phase 3 clinical trials for lowering cholesterol in patients with these metabolic conditions.
MK0653A combines ezetimibe and simvastatin. Ezetimibe targets the intestinal cholesterol absorption pathway, while simvastatin targets HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. Together they reduce LDL cholesterol through complementary mechanisms.
MK0653A is developed by Organon & Co., which trades under the ticker OGN. Organon is the sponsor of the clinical trials evaluating this ezetimibe and simvastatin combination.
MK0653A is in Phase 3 clinical development. All six of its registered trials have been completed, and there are currently no active trials. The program has enrolled a total of 8,104 participants across its studies.
MK0653A has been evaluated in completed Phase 3 trials including NCT00541697 in type 2 diabetes, NCT00132717 in hypercholesterolemia, NCT00110435 in type 2 diabetes and hypercholesterolemia, and NCT00092690 comparing it to atorvastatin for high cholesterol.
Yes, MK0653A is also known as ezetimibe simvastatin, ezetimibe (+) simvastatin, and MK0653A (ezetimibe [+] simvastatin). These names refer to the same fixed-dose combination product studied in the Phase 3 program.